Keyphrases
Semaglutide
49%
Type 2 Diabetes Mellitus (T2DM)
48%
Type 2 Diabetic Patients
32%
Hemoglobin A1c (HbA1c)
24%
Once-weekly Semaglutide
24%
Placebo
23%
Overweight or Obesity
22%
Insulin
18%
Metformin
18%
Glucagon-like
16%
Liraglutide
16%
Receptor Agonist
15%
A1 Receptor
15%
Weight Loss
14%
Diabetes
13%
Cardiovascular Outcomes
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
11%
Cardiovascular Risk
11%
Basal Insulin
11%
Obesity
10%
Confidence Interval
10%
Cardiovascular Disease
10%
Once-weekly
9%
Insulin Degludec
9%
Hepatic Steatosis
9%
Oral Semaglutide
8%
Glycemic Control
8%
Canagliflozin
8%
Randomized Clinical Trial
8%
Icodec
8%
Once-daily
8%
Treatment Difference
8%
Body Mass Index
7%
Heart Failure
7%
Insulin Icodec
7%
Major Adverse Cardiovascular Events
7%
Once-weekly Insulin
7%
Without Diabetes
7%
Randomized Trial
6%
Cardiovascular Risk Reduction
6%
Gastrointestinal Side Effects
6%
Baseline Characteristics
6%
Dulaglutide
6%
Subcutaneous Semaglutide
6%
Hypoglycemia
5%
Glargine U100
5%
Cardiovascular Events
5%
Insulin Dose
5%
GLP-1 Receptor Agonist
5%
Cardiovascular Effects
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Semaglutide
89%
Hemoglobin A1c
37%
Placebo
36%
Metformin
25%
Obesity
25%
Hypoglycemia
23%
Glucagon Like Peptide 1 Receptor Agonist
22%
Liraglutide
22%
Cardiovascular Disease
21%
Heart Failure
19%
Insulin Glargine
17%
Pig Insulin
16%
Insulin Degludec
16%
Adverse Event
15%
Randomized Clinical Trial
14%
Cardiovascular Risk
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Randomized Controlled Trial
12%
Glycosylated Hemoglobin
11%
Insulin Dependent Diabetes Mellitus
10%
Canagliflozin
10%
Dulaglutide
8%
Cardiomyopathy
7%
Fatty Liver
7%
Triacylglycerol
7%
Symptom
6%
Empagliflozin
6%
Chronic Kidney Failure
5%
Tolerability
5%
Disease
5%
Medicine and Dentistry
Semaglutide
69%
Maturity Onset Diabetes of the Young
53%
Diabetes
37%
Patient with Type 2 Diabetes
29%
Cardiovascular System
27%
Placebo
27%
Obesity
24%
Glycon
23%
Hemoglobin A1c
21%
Cardiovascular Disease
19%
Glucagon-Like Peptide-1 Agonist
19%
Heart Failure
18%
Liraglutide
14%
Drug Therapy
13%
Sodium Glucose Cotransporter 2 Inhibitor
13%
Canagliflozin
12%
Cardiovascular Risk
12%
Adverse Event
11%
Body Mass Index
10%
Disease
10%
Randomized Clinical Trial
9%
Body Weight
9%
Steatosis
8%
Statin
8%
Post-Hoc Analysis
7%
Bariatric Surgery
6%
Apoplexy
6%
Triacylglycerol
6%
Cell Function
6%
Risk Reduction
6%
Glycemic Control
6%
Symptom
5%
Hypoglycemia
5%
Nephropathy
5%
Cardiology
5%
Drug Megadose
5%
Fatty Liver
5%
Cardiomyopathy
5%
